Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Icad Inc (ICAD)

Icad Inc (ICAD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 54,672
  • Shares Outstanding, K 26,540
  • Annual Sales, $ 17,320 K
  • Annual Income, $ -4,850 K
  • EBIT $ -6 M
  • EBITDA $ -5 M
  • 60-Month Beta 1.40
  • Price/Sales 2.87
  • Price/Cash Flow N/A
  • Price/Book 1.80

Options Overview Details

View History
  • Implied Volatility 120.61% ( +2.77%)
  • Historical Volatility 68.66%
  • IV Percentile 16%
  • IV Rank 20.75%
  • IV High 434.25% on 02/16/24
  • IV Low 38.52% on 08/23/24
  • Put/Call Vol Ratio 0.03
  • Today's Volume 157
  • Volume Avg (30-Day) 81
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 1,926
  • Open Int (30-Day) 2,149

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +666,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.65 +24.84%
on 12/04/24
2.15 -4.19%
on 01/03/25
+0.36 (+21.18%)
since 12/03/24
3-Month
1.34 +54.31%
on 10/11/24
2.42 -14.88%
on 11/13/24
+0.53 (+34.64%)
since 10/03/24
52-Week
1.18 +74.58%
on 07/05/24
2.65 -22.26%
on 03/05/24
+0.28 (+15.73%)
since 01/03/24

Most Recent Stories

More News
The Next Wave of Health AI: Analysts Highlight Breakthroughs in Clinical Trials and Patient Care

USA News Group  Commentary Issued on behalf of Avant Technologies Inc.   Vancouver, BC – December 17, 2024  – USA News Group News Commentary – Artificial intelligence (AI) is on the brink of becoming...

HWAIF : 1.4000 (-3.30%)
AIDX.TO : 2.00 (-3.38%)
AVAI : 0.4855 (+0.10%)
BTAI : 0.4140 (+5.61%)
RDNT : 71.51 (+1.94%)
ICAD : 2.06 (+3.52%)
iCAD, Inc. Announces Presentation of Four Novel AI-Driven Breast Cancer Research Abstracts at 2024 San Antonio Breast Cancer Symposium

iCAD announced acceptance of four AI-driven breast cancer abstracts for presentation at the 2024 SABCS, focusing on detection and risk assessment.Quiver AI SummaryiCAD, Inc., a leader in AI-powered cancer...

ICAD : 2.06 (+3.52%)
SABCS 2024: New Research Assesses iCAD’s Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse Populations

ICAD : 2.06 (+3.52%)
iCAD, Inc. Partners with Cascaid Health to Launch ProFound Health at RSNA 2024, Expanding Access to AI-Driven Breast Health Solutions

iCAD announces collaboration with Cascaid Health to enhance access to AI-driven breast health solutions at RSNA 2024.Quiver AI SummaryiCAD, Inc. announced that it will showcase its advanced breast health...

ICAD : 2.06 (+3.52%)
CORRECTION – iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and ProFound Health Partnership with Cascaid Health at RSNA 2024

ICAD : 2.06 (+3.52%)
iCAD, Inc. Showcases AI-Powered Breast Health Innovations and Partnership with Cascaid Health at RSNA 2024

iCAD will present AI-driven breast health solutions at RSNA 2024, showcasing new technology and partnerships to improve cancer detection.Quiver AI SummaryiCAD, Inc., a leading provider of AI-powered cancer...

ICAD : 2.06 (+3.52%)
iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024

ICAD : 2.06 (+3.52%)
Icad: Q3 Earnings Snapshot

Icad: Q3 Earnings Snapshot

ICAD : 2.06 (+3.52%)
iCAD Reports Financial Results for Third Quarter Ended September 30, 2024

ICAD : 2.06 (+3.52%)
iCAD's ProFound Detection Version 4.0 Gains FDA Clearance

ICAD : 2.06 (+3.52%)

Business Summary

Icad, Inc. designs, engineers, develops and manufactures digital image scanners, densitometers, film digitizers and related software for applications in the graphic arts, medical imaging and life sciences markets. The Company sells its products throughout the world throughvarious distributors, resellers,...

See More

Key Turning Points

3rd Resistance Point 2.33
2nd Resistance Point 2.24
1st Resistance Point 2.15
Last Price 2.06
1st Support Level 1.97
2nd Support Level 1.88
3rd Support Level 1.79

See More

52-Week High 2.65
Fibonacci 61.8% 2.09
Last Price 2.06
Fibonacci 50% 1.91
Fibonacci 38.2% 1.74
52-Week Low 1.18

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar